Taiwan Liposome Company
Taipei City, Taiwan· Est.
Taiwanese biotech leveraging next‑gen lipid delivery for pain, metabolic and cell‑therapy medicines.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Taiwanese biotech leveraging next‑gen lipid delivery for pain, metabolic and cell‑therapy medicines.
OrthopedicsPain ManagementMetabolic DisordersImmune DisordersInfectious DiseasesRegenerative Medicine
Technology Platform
LipAD® platform – a family of lipid‑assembled delivery systems (BioSeizer®, NanoX®, Genosphere™) that enable sustained release, high drug loading and targeted tissue delivery for small molecules, peptides and nucleic acids.
Opportunities
Late‑stage data read‑outs for TLC599 and TLC518 could drive first commercial launches, while the Genosphere™ CAR‑T platform opens high‑value cell‑therapy markets.
Risk Factors
Competition from larger lipid‑nanoparticle developers, regulatory hurdles for novel delivery systems, and the need for substantial capital to fund Phase 3 trials and manufacturing scale‑up.
Competitive Landscape
TLC competes with firms such as Moderna, BioNTech, and other lipid‑nanoparticle specialists, but differentiates through its sustained‑release BioSeizer® and targeted Genosphere™ technologies aimed at pain, metabolic and cell‑therapy indications.